Hematopoietic neoplasms associated with FGFR1 rearrangement are included in the family of myeloid and lymphoid neoplasms with varying responsiveness to TKIs, though other neoplasms such as AMLs, ALLs, and MPSs with FGFR3 are characterized by aggressive clinical behavior and resistance to imatinib [176]. The gene discussed is FGFR1; the disease is lymphoid neoplasm.